Zepbound Use Associated With Lower Healthcare Costs
INDIANAPOLIS, Aug. 26, 2026 — Eli Lilly and Company announced new real-world evidence showing that sustained use of Zepbound (tirzepatide) for weight management was associated with lower healthcare costs among adults over age 55 with overweight or obesity. The retrospective study compared 15,843 adults who initiated Zepbound with matched untreated individuals and found that healthcare costs were lower over time among patients who remained on treatment. Importantly, the analysis excluded the cost of Zepbound itself, meaning the findings represent potential savings in other areas of healthcare rather than the overall net cost of treatment. The study was published in Diabetes, Obesity and Metabolism and represents a significant addition to the growing body of real-world evidence examining the healthcare utilization and economic impact of obesity treatment in older adults.
Lower Hospital and Emergency Department Utilization
The analysis found that sustained Zepbound treatment was associated with fewer hospital admissions and emergency department visits across follow-up periods in the primary analysis. At six months, estimated healthcare costs were up to 15% lower, corresponding to savings of as much as $181 per patient per month compared with untreated adults. By 12 months, the difference increased substantially, with estimated savings reaching as much as $607 per patient per month, representing an average of up to 38% lower healthcare costs. Researchers used two complementary analytical approaches, including a primary inverse probability of censoring weighting analysis and a secondary pairwise analysis, and both approaches showed a consistent direction toward lower monthly healthcare costs with sustained Zepbound use. The findings also showed numerically greater routine outpatient and office visits among treated individuals, potentially reflecting greater engagement with ongoing healthcare management rather than reliance on acute-care services.
Findings Support Growing Focus on Obesity Economics
For Eli Lilly, the findings extend the potential value proposition of Zepbound beyond weight reduction by highlighting its possible relationship with healthcare resource utilization and medical cost trends in an aging population. The study included adults with obesity or overweight accompanied by at least one obesity-related complication and used de-identified claims data from a large U.S. healthcare database. Estimated savings began to approach the $195 monthly treatment cost associated with Medicare’s GLP-1 Bridge program at around six months, while at 12 months the estimated healthcare cost reduction exceeded that monthly amount in the study’s models. However, the company emphasized that claims data do not capture Zepbound’s net price, so the results should not be interpreted as proof that treatment produces an overall net reduction in healthcare spending. Instead, the findings indicate that reduced hospital and emergency care costs could potentially offset part of the treatment expense as sustained obesity management becomes more widely adopted.
Advertisement
Real-World Evidence Strengthens Zepbound Value Story
The study adds another dimension to the expanding real-world evidence base surrounding Zepbound and tirzepatide-based obesity treatment, particularly as healthcare systems and payers evaluate the long-term consequences of untreated obesity. Zepbound is a dual GIP and GLP-1 receptor agonist approved for chronic weight management in eligible adults and is also approved for adults with obesity and moderate-to-severe obstructive sleep apnea. The latest analysis does not establish a causal relationship between Zepbound use and lower healthcare costs because it is an observational claims-based study, but the consistency between the two analytical methods strengthens the reported association. For Eli Lilly, the results provide additional evidence that sustained obesity treatment may influence healthcare utilization beyond weight-related outcomes, particularly among adults over 55. The findings could become relevant to Medicare, employers, insurers and other healthcare decision-makers assessing the economic implications of broader access to GLP-1-based obesity therapies.
Source:Eli Lilly press relese
